A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard)

BACKGROUND. Capecitabine administered for 7 days biweekly with oxaliplatin (XELOX) biweekly has been reported to have activity and safety profiles similar to those of standard capecitabine given for 14 days triweekly. Multiple studies have shown that the addition of bevacizumab to 5-fluorouracil–bas...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Hurwitz, Herbert, Mitchell, Edith P., Cartwright, Thomas, Kwok, Ambrose, Hu, Sylvia, McKenna, Edward, Patt, Yehuda Z.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2012
Témata:
Gastrointestinal Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399650/
https://ncbi.nlm.nih.gov/pubmed/22622147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0071
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky